Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone.
about
Osteoclasts are active in bone forming metastases of prostate cancer patientsSecreted Frizzled-related protein-1 is a negative regulator of androgen receptor activity in prostate cancerThe role of RANK-ligand inhibition in cancer: the story of denosumabOsteoprotegerin rich tumor microenvironment: implications in breast cancerBone Tumor Environment as a Potential Therapeutic Target in Ewing SarcomaThe Modulatory Effects of Mesenchymal Stem Cells on OsteoclastogenesisUse of Animal Models in Understanding Cancer-induced Bone PainTargeting RANKL in metastasisOsteoprotegerin in bone metastases: mathematical solution to the puzzleCharacterization of osteoblastic and osteolytic proteins in prostate cancer bone metastases.Host-derived RANKL is responsible for osteolysis in a C4-2 human prostate cancer xenograft model of experimental bone metastases.A genetic polymorphism of the osteoprotegerin gene is associated with an increased risk of advanced prostate cancer.Multiple roles of chemokine (C-C motif) ligand 2 in promoting prostate cancer growth.RANK rs1805034 T>C polymorphism is associated with susceptibility of esophageal cancer in a Chinese population.Reversal of chemotherapy-induced leukopenia using granulocyte macrophage colony-stimulating factor promotes bone metastasis that can be blocked with osteoclast inhibitorsShedding of RANKL by tumor-associated MT1-MMP activates Src-dependent prostate cancer cell migration.Therapeutic potential of adult bone marrow-derived mesenchymal stem cells in prostate cancer bone metastasisEwing sarcoma cells express RANKL and support osteoclastogenesis.Bisphosphonates regulate cell proliferation, apoptosis and pro-osteoclastic expression in MG-63 human osteosarcoma cells.Biology of the RANKL-RANK-OPG System in Immunity, Bone, and Beyond.Expression of colony-stimulating factor 1 receptor during prostate development and prostate cancer progressionCanine prostate cancer cell line (Probasco) produces osteoblastic metastases in vivoBone Metastasis of Prostate Cancer Can Be Therapeutically Targeted at the TBX2-WNT Signaling Axis.Activation of NF-kappa B signaling promotes growth of prostate cancer cells in bone.Animal models of bone metastasis.Regulation of gene expression and inhibition of experimental prostate cancer bone metastasis by dietary genisteinRole of RANKL and RANK in bone loss and arthritis.Bone resorption facilitates osteoblastic bone metastatic colonization by cooperation of insulin-like growth factor and hypoxia.Molecular signaling pathways mediating osteoclastogenesis induced by prostate cancer cells.Human mesenchymal stem cells as delivery of osteoprotegerin gene: homing and therapeutic effect for osteosarcoma.Evaluation of rs3102735 and rs2073617 Osteoprotegerin Gene Polymorphisms and the Risk of Childhood Acute lymphoblastic Leukemia in Zahedan Southeast Iran.Butein, a tetrahydroxychalcone, suppresses cancer-induced osteoclastogenesis through inhibition of receptor activator of nuclear factor-kappaB ligand signalingThe use of zoledronic acid in the management of metastatic bone disease and hypercalcaemia.Lack of noggin expression by cancer cells is a determinant of the osteoblast response in bone metastases.The PCa Tumor Microenvironment.Variants of Osteoprotegerin Lacking TRAIL Binding for Therapeutic Bone Remodeling in Osteolytic Malignancies.Receptor activator of nuclear factor kappaB ligand (RANKL)/osteoprotegerin (OPG) ratio is increased in severe osteolysisProstate cancer-associated membrane type 1-matrix metalloproteinase: a pivotal role in bone response and intraosseous tumor growth.Regulatory T cells in the bone marrow microenvironment in patients with prostate cancerAnti-IL-20 Monoclonal Antibody Suppresses Prostate Cancer Growth and Bone Osteolysis in Murine Models.
P2860
Q21090081-B90F0753-D4F8-472D-865C-3B3067E0062EQ24319970-46C2039D-B5F9-4C09-914E-39F573D534E0Q24633284-33AF0362-1A24-44E8-9AD9-D72A5CF3EEB8Q26748804-FD53EB0D-C4D0-46FC-9218-87BF8D9B463DQ26771376-741DC92B-81EA-48BC-A2B9-E63E5E6CEF3AQ26773017-BE0EA2CF-879B-4BC6-BDA5-3CE136CA63D1Q26785501-CB3BA02F-B893-4A86-8D4C-57E07B006B72Q26849690-10579FAE-B55D-44EB-B28A-49E04B390B47Q27329714-C6AD61F5-BB8C-4DBA-AB1C-180CC604F26EQ30596578-459D3C5E-7C53-406A-BBFB-5A6C9215EFC2Q33293423-F5606286-5863-4F03-9FC5-D1B44D5B0C37Q33358300-772F019B-1CCB-4D70-91FD-EF0E442E1157Q33803085-89AB7739-4257-4077-A9E9-420C9F573DAAQ33895612-AEB20B7B-50B5-41B6-A208-2FF3197BFA50Q33926132-B26921C6-9EBD-4D57-BDB5-7052EBE2F8F7Q33958982-14DE91D9-275B-4F1E-AC0F-B598BA6CE7DBQ34147824-3FFD8A8A-DA75-4FCA-B1F9-B2E3670AEEF7Q34183161-1D0CF2BB-1DC3-414D-BBDC-7D17D524F9C1Q34356336-F000F92E-5CD8-4E36-AEF7-C4467E7487B8Q34366449-C79C083B-90EA-4F32-814B-C786327C1517Q34394070-88CB3CE5-98ED-4B9D-B291-41B0AD08AA9FQ34438300-7F779CDB-D10F-4F36-82FF-593EE30A39CBQ34549787-B0222048-E0FF-448D-A089-957C1CBF097EQ34664057-B8558AF1-048E-4F94-AA10-8BA95A81AFE6Q34675085-E0D7FBB7-2F8A-4454-93A4-D9D66CD53B03Q34770095-FC4851B3-678A-4907-9D56-A111441A27B0Q34963016-2F73F93F-295E-4CE3-8547-C1D3116251A9Q35051528-F63E4386-96CD-4FDB-B84D-016A13F3EC39Q35076418-A607D342-EB32-4A5A-800D-77491F090478Q35115283-0E9FEAAE-ACAA-4389-897C-19601C98F292Q35133898-C11C30A9-C6A1-4BB0-ABAF-E28DCB48A3C7Q35511177-92E7AC71-FED2-4332-838A-B815EDEB53D9Q35550375-B301DDD8-AB8C-4B15-BC31-8F53B3363EC2Q35570431-B8039355-FE14-447F-A40C-06BABC1CC9BAQ35603143-CFB0155C-2B01-44E4-84BF-ABA267D011E6Q35611366-AEEFEE96-4A23-46E0-9CB6-581F1D7C14C1Q35843398-8C13A944-7C69-42F2-8BCE-225BFDFD01F8Q35855547-302DD8E0-C508-4514-891F-21D52E15955EQ36038429-785973D9-2BC8-4346-A28A-E332059A3FD0Q36126224-76A558A5-BB02-4933-AB5B-79A3EBE543CD
P2860
Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh
2001年學術文章
@zh-hant
name
Osteoprotegerin inhibits prost ...... tate tumor growth in the bone.
@en
Osteoprotegerin inhibits prost ...... tate tumor growth in the bone.
@nl
type
label
Osteoprotegerin inhibits prost ...... tate tumor growth in the bone.
@en
Osteoprotegerin inhibits prost ...... tate tumor growth in the bone.
@nl
prefLabel
Osteoprotegerin inhibits prost ...... tate tumor growth in the bone.
@en
Osteoprotegerin inhibits prost ...... tate tumor growth in the bone.
@nl
P2093
P2860
P356
P1476
Osteoprotegerin inhibits prost ...... tate tumor growth in the bone.
@en
P2093
A Mizokami
C Strayhorn
E T Keller
P2860
P304
P356
10.1172/JCI11685
P407
P577
2001-05-01T00:00:00Z